Loren K Mell, MD, Moores UC San Diego Cancer Center
Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer
Cancer of Head and Neck
The purpose of this study is to determine the safety and tolerability of GL-ONC1
administered intravenously in combination with radiation therapy and cisplatin (CDDP)in
patients with locoregionally advanced head and neck cancer.
Ages Eligible: 18 Years
Accepts Healthy Volunteers:
Confirmed diagnosis of histologically or cytologically documented Stage III to IVB
primary, non-metastatic head and neck cancer for newly diagnosed patients with no
prior disease-related treatment (e.g., chemotherapy, radiation treatment, surgery,
American Joint Committee on Cancer (AJCC) Stage III-IVB disease (2010 manual, 7th
edition), based on standard diagnostic workup.
18 years or older.
ECOG performance status of ≤ 2.
Laboratory data obtained within 14 days prior to Treatment Day 1, with adequate
hepatic and renal function defined as follows:
- Absolute neutrophil count (ANC) ≥ 1,800 cells/mm3;
- Platelets ≥ 100,000 cells/mm3;
- Hemoglobin ≥ 8.0 g/dL;
- Bilirubin ≤ 1.5 mg/dL;
- AST or ALT ≤ 2× upper limit of normal (ULN);
- Serum creatinine ≤ 1.5 mg/dL;
- Creatinine clearance (CC) ≥ 50 mL/min.
Pulse oximetry reading of 92% or higher at rest on room air.
Signed informed consent
Women of childbearing potential must have a negative serum pregnancy test and agree
to practice effective birth control during treatment phase and up to 60 days after
the last virus application.
Male patients must agree to practice effective birth control during the study and for
60 days following administration of last treatment of virus.
Clinical, radiographic, or pathologic evidence of distant metastatic disease.
Patients with fever, active immunosuppressive systemic infection or a suppressed
immune system, including AIDS or HIV positivity and known hepatitis infections (HCV
or HBC. Eligible patients must have an HIV test conducted within 4 weeks prior to
study enrollment with a negative test result.
Any form of prior anti-cancer treatment.
Disease-related surgery, excluding biopsy.
Patients with CNS (Central Nervous System) tumors.
Any other open wounds.
Concurrent small pox vaccination for 4 weeks before study therapy and during study
Patients on immunosuppressive therapy or with immune system disorders, including
Previous organ transplantation.
Patients with clinically significant dermatological disorders, as judged by the
clinical investigator (e.g., eczema or psoriasis), any skin lesions or ulcers, any
history of atopic dermatitis, or any history of Darier's disease (Keratosis
Clinically significant cardiac disease (New York Heart Association: Class III or IV).
Dementia or altered mental status that would prohibit informed consent.
Known allergy to ovalbumin or egg products.
Prior gene therapy treatments or prior therapy with cytolytic virus of any type.
Moores UC San Diego Cancer Center
La Jolla, California, 92037
Back to Search Results
Information objtained from ClinicalTrials.gov, on
10/31/2014. For additional information about
this and other clinical trials,
Please refer to this study by its ClinicalTrials.gov identifier: